Komori
Changes in Officers4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Regarding the Assignment of Responsibilities to Directors and Executive Officers of a Subsidiary

As of 24 June 2026, the company determined the management structure of its subsidiaries and the responsibilities assigned to its executive officers. In addition, 1 executive officer of あすか製薬 and 1 director of あすか製薬メディカル retired as of the same date.

Worth reading
50Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Resolved 24 June 2026

Departing officer

1 item
Date of departure24 June 2026
Seki Hiroto (関 浩人), Saito Junichi (齋藤 淳一)Next role stated
Former PositionExecutive officer (Seki Hiroto (関 浩人)); director (Saito Junichi (齋藤 淳一))
New positionRetirement

“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.

Scheduled Appointment Date24 June 2026 (determined as of the same date)
Whether the incumbent will remain in office (whether they will retain their position)

No statement that the individual will remain on the board

Directors after the change6Number
Who is moving to which position
ItemDetails
Resolution date24 June 2026
Scheduled Appointment Date24 June 2026 (determined as of the same date)
Date of departure24 June 2026
Name of departing officerSeki Hiroto (関 浩人), Saito Junichi (齋藤 淳一)
Former position of departing officerExecutive officer (Seki Hiroto (関 浩人)); director (Saito Junichi (齋藤 淳一))
New position of departing officerRetirement
Whether the incumbent will remain in officeNo statement that the individual will remain on the board
Number of directors after the changeあすか製薬株式会社: 6; あすかアニマルヘルス株式会社: 3; 株式会社あすか製薬メディカル: 2. The number of outside directors is Not disclosed
Items this document does not state (13)
Name of appointeeAppointee's new positionAppointee's previous positionAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company has provided no specific explanation for the changes.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Assignment of Responsibilities to Directors and Executive Officers of a Subsidiary | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori